-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
KEYNOTE-061 is a randomized, open-label, phase 3 clinical trial that evaluates the efficacy of Pembrolizumab vs.
KEYNOTE-061 is a randomized, open-label, phase 3 clinical trial that evaluates the efficacy of Pembrolizumab vs.
When data is turned off, 366 cases of PD-L1 CPS≥1 patients died (daclizumab group Pabo Li 176/196 [89.
When data is turned off, 366 cases of PD-L1 CPS≥1 patients died (daclizumab group Pabo Li 176/196 [89.
OS
Among patients with P D -L1 CPS≥1 and ECOG PS=0, the median OS of the pembrolizumab group and the paclitaxel group were 12.
Among patients with P D -L1 CPS≥1 and ECOG PS=0, the median OS of the pembrolizumab group and the paclitaxel group were 12.
Comparison of OS with different PS scores
In patients with PD-L1 CPS≥1, the median PFS of the pembrolizumab group and paclitaxel group were 1.
In patients with PD-L1 CPS≥1, the median PFS of the pembrolizumab group and paclitaxel group were 1.
PFS
ORR (pembrolizumab vs paclitaxel) were 16.
ORR (pembrolizumab vs paclitaxel) were 16.
Treatment-related adverse reactions in the pembrolizumab group were less than those in the paclitaxel group, which were 53% and 84%, respectively
In summary, the study shows that with the increase of PD-L1 expression, pembrolizumab can improve the OS of gastric or gastroesophageal junction cancer compared with paclitaxel, and has fewer adverse reactions
.
The study showed that with the increase of PD-L1 expression, pembrolizumab can improve the OS of gastric or gastroesophageal junction cancer compared with paclitaxel, and has fewer adverse reactions
.
The study showed that with the increase of PD-L1 expression, pembrolizumab can improve the OS of gastric or gastroesophageal junction cancer compared with paclitaxel, and has fewer adverse reactions
.
Original source:
Original source:Fuchs CS, Özgüroğlu M, Bang YJ, et al.
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Gastric Cancer.
2021 Sep 1 .
doi: 10.
1007/s10120-021-01227-z.
Epub ahead of print.
PMID: 34468869.
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Gastric Cancer.
2021 Sep 1 .
doi: 10.
1007/s10120-021-01227-z.
Epub ahead of print.
PMID: 34468869.
Leave a message here
